Table 1.
Demographic and biomarker data
| Characteristic | PiB+ | PiB– | p |
| N | 49 | 150 | NA |
| Female, % | 43% | 65% | <0.01* |
| Age at LP, y | 72.4±7.3 | 64.2±9.6 | <0.001 |
| % APOE ɛ4 carriers | 58% | 31% | <0.01* |
| Education, y | 15.4±2.9 | 15.9±2.5 | 0.283 |
| MMSE | 28.00±3.03 | 29.07±1.21 | 0.02 |
| Median LP-PiB PET interval (IQR), days | 24 (16 –64) | 33 (12–94) | 0.45† |
| PiB MCBP | 0.5275±0.2454 | 0.0473±0.0502 | <0.001 |
| CSF Aβ40, pg/mL | 15 280±4 160 | 13 890±4 260 | 0.047 |
| CSF Aβ42, pg/mL | 577±184 | 887±292 | <0.001 |
| CSF Aβ42/40 | 0.038±0.009 | 0.065±0.013 | <0.001 |
| CSF Tau, pg/mL | 492±392 | 234±125 | <0.001 |
| CSF pTau181, pg/mL | 75.8±35.3 | 47.2±19.1 | <0.001 |
*χ2 test. †Mann-Whitney test. APOE, apolipoprotein E; CSF, cerebrospinal fluid; IQR, interquartile range; LP, lumbar puncture; MCBP, mean cortical binding potential; MMSE, Mini-Mental State Examination (0–30, with 30 a perfect score) at clinical assessment closest in time to LP; NA, not applicable; PET, positron emission tomography; PiB, Pittsburgh Compound B. Unless otherwise indicated, values represent the mean±SD.